Omeprazole Sulfone: Reference Standard Applications, Generic Drug Testing, and Global Forecast

Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Omeprazole Sulfone – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Omeprazole Sulfone market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Omeprazole Sulfone was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5975350/omeprazole-sulfone

1. Core Market Definition & Critical Pain Points

In pharmaceutical quality control, regulatory agencies (FDA, EMA, NMPA) require stringent impurity profiling of active pharmaceutical ingredients (APIs) and finished products. Omeprazole sulfone is the major degradation product and oxidative metabolite of omeprazole (Prilosec®), a proton pump inhibitor (PPI) used for gastroesophageal reflux and peptic ulcers. For QC laboratories, generic drug manufacturers, pharma compliance officers, and analytical chemists, core needs include high-purity reference standards (≥99.5%), stability-indicating methods, and compliance with ICH Q3A/Q3B impurity limits.

2. Market Size & Recent 6-Month Trajectory (Q4 2025 – Q2 2026)

According to QYResearch’s latest tracking (integrating company annual reports, securities disclosures, and pharma supply data), the global Omeprazole Sulfone market is niche but steadily growing:

2025 estimated value: US$ million (full report)
2032 projected value: US$ million
Implied CAGR (2026-2032): %

Observed six-month trends:

Powder form dominates (≈70-75% of market) – reference standard for HPLC/LC-MS methods
Tablet form used in finished product dissolution testing (comparators for generic ANDA filings)
Hospital and pharmacy segments reflect end-use of omeprazole itself (not the sulfone) – sulfone is an intermediate/test material, not prescribed
Geographic hotspots: North America (FDA reference standard demand), Europe (EDQM), Asia-Pacific (generic API manufacturing hubs – China, India)

3. Key Industry Development Characteristics (2021–2026)

3.1 Form Segmentation: Powder vs. Tablets

Form	Typical Purity	Primary Application	Users	Key Requirement
Powder (reference standard)	≥99.5% (certified)	Impurity identification, quantification (HPLC), stability studies	Pharma QC labs, CROs, regulatory agencies	COA with traceability to USP/EP reference
Tablets (placebo or spiked)	Formulated (contains sulfone at specified level)	Dissolution testing (comparator for generic products), method validation	Generic drug manufacturers, ANDA filers	Simulated finished product matrix

Key trend: Powder reference standards are the largest segment, driven by regulatory requirement for impurity testing of omeprazole APIs and finished products (ICH limit: sulfone ≤0.15% for omeprazole).

3.2 Role in Generic Drug Development

Exclusive industry observation: Omeprazole sulfone is critical for ANDA (Abbreviated New Drug Application) filings:

Stress degradation studies: Omeprazole degrades to sulfone under oxidative conditions (H₂O₂). Applicants must demonstrate method specificity (sulfone peak resolved from API and other impurities).
Stability-indicating methods: Stability batches tested for sulfone content (acceptable limit: NMT 0.2-0.5% depending on pharmacopoeia).
Reference standard qualification: USP provides official omeprazole sulfone RS (Catalog #1478208). Non-USP sources require full characterization (NMR, MS, HPLC purity).

Market implication: Each generic omeprazole ANDA filing (and post-approval stability batch) consumes milligram-to-gram quantities of sulfone reference standard. With 50+ omeprazole generics globally, this drives recurring demand.

4. Competitive Landscape & Leading Players (QYResearch 2026 Database)

Based on verified annual reports, securities disclosures, and pharma reference standard suppliers:

CAYMAN CHEMICAL – Major supplier of research-grade omeprazole sulfone (≥98%, not USP-grade). Used in non-GMP R&D (method development).
Shouguang Fukang Pharmaceutical Co., Ltd – Chinese API manufacturer; produces sulfone as impurity standard; exports to generic drug makers.
Yuekang Pharmaceutical Group Co., Ltd – Another Chinese API/impurity supplier; provides COA with HPLC purity (>99%).
Shenyang Pharmaceutical University – Academic supplier (small quantities for research).
Zhengda Tianqing – Chinese pharma; internal use for QC (not typically sold externally).
AstraZeneca – Innovator of omeprazole (Prilosec®). Uses sulfone for in-house QC; may not sell externally.
Mylan , Teva Pharmaceuticals , Dr. Reddy’s Laboratories , Perrigo Company , Sandoz , Apotex – Major generic manufacturers. They purchase sulfone reference standards (from specialized suppliers) for ANDA filings and stability testing, but do not typically sell sulfone themselves.

Strategic insight: The Omeprazole Sulfone market is highly fragmented on the supply side (specialty chemical/impurity vendors) with demand from generic pharma. CAYMAN and Chinese suppliers lead. No single player dominates >15-20% share.

5. End-Use Application Deep Dive & User Cases

5.1 Hospital / Pharmacy Segment (~15-20% of market value – indirect)

Note: Hospitals and pharmacies use omeprazole (API or finished product), not omeprazole sulfone directly. The sulfone segment here refers to QC testing of omeprazole batches used in these settings.

User case (Q1 2026) : A hospital pharmacy receives omeprazole 20mg capsules from a generic manufacturer (Teva). Prior to dispensing, the hospital’s QC lab tests a random sample for impurities including omeprazole sulfone (per USP monograph). Method uses HPLC-UV, sulfone reference standard (purchased from CAYMAN). Result: 0.08% sulfone (within USP limit <0.2%). Batch released.

Regulatory requirement: USP-NF requires omeprazole drug substance to contain not more than (NMT) 0.15% of omeprazole sulfone; finished product NMT 0.2%.

5.2 Other (QC Labs, R&D, CROs) (~80-85% of market value)

Primary activities:

Method development/validation (new generic omeprazole products)
Stability studies (accelerated 40°C/75% RH, long-term 25°C/60% RH)
Storage condition excursion testing (e.g., photostability – sulfone increases under light)

User case (Q2 2026) : A CRO (Contract Research Organization) is developing a new omeprazole delayed-release tablet for a client. As part of forced degradation studies, they expose the formulation to 0.3% H₂O₂ for 24 hours. HPLC analysis (using omeprazole sulfone reference standard from Yuekang) shows 1.8% sulfone formation, demonstrating that the formulation is susceptible to oxidation. Client adds an antioxidant (BHT) to the formulation. Revised stability batch shows sulfone <0.15% at 6 months.

6. Technical Challenges & Industry Response

Critical unresolved issue #1: Reference standard stability – Omeprazole sulfone degrades further under heat/light (to other impurities), limiting shelf life of reference standards.

Industry responses:

Deep-freeze storage (–20°C recommended, desiccated)
Unit-dose aliquoting (small vials to avoid repeated freeze-thaw)
Short-dating (certified reference standards typically 2-3 years expiration)

Critical unresolved issue #2: Lack of universal pharmacopeial standard – USP provides official reference standard, but expensive (>$300/vial). Many labs use in-house qualified standards from chemical suppliers (risk of purity differences).

Regulatory guidance (FDA, 2025): For ANDA filings, sponsors may use a “secondary reference standard” qualified against USP RS if fully characterized (NMR, assay, impurity profile). This reduces cost but requires validation.

Critical unresolved issue #3: Co-elution with other impurities – Omeprazole has multiple degradation products (sulfone, sulfide, N-oxide). Reverse-phase HPLC may not resolve all peaks, leading to over- or under-estimation of sulfone.

Mitigation:

Use of UPLC (improved resolution)
LC-MS/MS confirmation (selective ion monitoring)
Different stationary phases (e.g., phenyl-hexyl column)

7. Policy Drivers & Regional Dynamics

Regulatory standards (pharmacopoeias):
- USP-NF : Monograph for omeprazole drug substance and delayed-release capsules includes omeprazole sulfone limit test.
- EP (European Pharmacopoeia) : Similar limits; requires EP-certified reference standard (not interchangeable with USP – slightly different assay method).
- JP (Japanese Pharmacopoeia) : Harmonized with EP.
- ChP (Chinese Pharmacopoeia) : Includes omeprazole sulfone control; growing compliance enforcement.
ICH guidelines:
- ICH Q3A (impurities in new drug substances) : Reporting threshold 0.05%, identification threshold 0.10%, qualification threshold 0.15% for omeprazole sulfone.
- ICH Q3B (impurities in new drug products) : Similar limits; daily dose-based calculation.
Enforcement trends (2025-2026):
- FDA increased 483 observations for inadequate impurity control (including omeprazole sulfone) – 12 such citations in 2025.
- China NMPA requires sulfone testing for all omeprazole API imports (effective Jan 2026).

8. Forecast Summary & Strategic Recommendations

With a projected CAGR of % (2026-2032) , the global Omeprazole Sulfone market offers clear strategic imperatives:

For suppliers (CAYMAN, Chinese manufacturers) : Obtain USP/EP certification for reference standards to access high-margin regulatory markets. Offer unit-dose packaging (pre-weighed vials) to reduce waste and freeze-thaw degradation.
For generic drug manufacturers (Teva, Mylan, Dr. Reddy’s) : Qualify secondary reference standards to reduce cost (USP RS for initial qualification, then in-house for routine testing). Validate HPLC methods with forced degradation studies to ensure sulfone peak is specific.
For QC laboratories : Store reference standards at –20°C in sealed desiccated vials. Participate in proficiency testing programs (e.g., USP, EDQM) to ensure accurate sulfone quantification.

*To access the complete report with 10-year forecasts, competitive market share matrix, form analysis, and 25+ supplier profiles:*